Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit

被引:40
|
作者
Khakwani, A. [1 ]
Rich, A. L. [2 ]
Powell, H. A. [1 ,3 ]
Tata, L. J. [1 ]
Stanley, R. A. [4 ]
Baldwin, D. R. [2 ]
Duffy, J. P. [5 ]
Hubbard, R. B. [1 ,3 ]
机构
[1] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England
[2] Univ Nottingham Hosp, Dept Resp Med, Nottingham NG5 1PB, England
[3] Univ Nottingham, Nottingham Resp Res Unit, Nottingham NG5 1PB, England
[4] Hlth & Social Care Informat Ctr, Clin Audit Support Unit, Leeds LS1 6AE, W Yorkshire, England
[5] Univ Nottingham Hosp, Dept Thorac Surg, Nottingham NG5 1PB, England
关键词
lung neoplasm; survival; thoracic surgery; England; SURGICAL RESECTION; UK; MANAGEMENT; SWEDEN;
D O I
10.1038/bjc.2013.572
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In comparison with other European and North American countries, England has poor survival figures for lung cancer. Our aim was to evaluate the changes in survival since the introduction of the National Lung Cancer Audit (NLCA). Methods: We used data from the NLCA to identify people with non-small-cell lung cancer (NSCLC) and stratified people according to their performance status (PS) and clinical stage. Using Cox regression, we calculated hazard ratios (HRs) for death according to the year of diagnosis from 2004/2005 to 2010; adjusted for patient features including age, sex and co-morbidity. We also assessed whether any changes in survival were explained by the changes in surgical resection rates or histological subtype. Results: In this cohort of 120 745 patients, the overall median survival did not change; but there was a 1% annual improvement in survival over the study period (adjusted HR 0.99, 95% confidence interval (CI) 0.98-0.99). Survival improvement was only seen in patients with good PS and early stage (adjusted HR 0.97, 95% CI 0.95-0.99) and this was partly accounted for by changes in resection rates. Conclusion: Survival has only improved for a limited group of people with NSCLC and increasing surgical resection rates appeared to explain some of this improvement.
引用
收藏
页码:2058 / 2065
页数:8
相关论文
共 50 条
  • [21] Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer
    Reinmuth, Niels
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1647 - +
  • [22] Relationship between vascularity, age and survival in non-small-cell lung cancer
    LM Chandrachud
    N Pendleton
    DM Chisholm
    MA Horan
    AM Schor
    British Journal of Cancer, 1997, 76 : 1367 - 1375
  • [23] SURVIVAL IN EARLY-STAGE NON-SMALL-CELL LUNG-CANCER
    NESBITT, JC
    PUTNAM, JB
    WALSH, GL
    ROTH, JA
    MOUNTAIN, CF
    ANNALS OF THORACIC SURGERY, 1995, 60 (02): : 466 - 472
  • [24] Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival
    Vaz, Daniel
    Campainha, Sergio
    Antunes, Ana
    Conde, Sara
    Barroso, Ana
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [25] Morbidity and survival after bronchoplastic surgery for non-small-cell lung cancer
    Schinkel, C
    Mueller, C
    Reinmiedl, J
    Fuerst, H
    JOURNAL OF CARDIOVASCULAR SURGERY, 2000, 41 (04): : 637 - 640
  • [26] Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib
    McGrath, Alexandria C.
    Sandhu, Geeta
    Walpole, Euan
    McCaffrey, Elizabeth
    Hollingworth, Samantha A.
    ANTI-CANCER DRUGS, 2018, 29 (08) : 786 - 790
  • [27] SURVIVAL ANALYSIS OF UNTREATED PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
    VRDOLJAK, E
    MISE, K
    SAPUNAR, D
    ROZGA, A
    MARUSIC, M
    CHEST, 1994, 106 (06) : 1797 - 1800
  • [28] The effect of lymph node ratio on survival in non-small-cell lung cancer
    Sezen, Celal Bugra
    Kalafat, Cem Emrah
    Dogru, Mustafa Vedat
    Aker, Cemal
    Erdogu, Volkan
    Saydam, Ozkan
    Metin, Muzaffer
    ACTA CHIRURGICA BELGICA, 2023, 123 (01) : 36 - 42
  • [29] Specific organ metastases and survival in metastatic non-small-cell lung cancer
    Tamura, Tomohiro
    Kurishima, Koichi
    Nakazawa, Kensuke
    Kagohashi, Katsunori
    Ishikawa, Hiroichi
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (01) : 217 - 221
  • [30] HORMONE REPLACEMENT THERAPY AND SURVIVAL OF WOMEN WITH NON-SMALL-CELL LUNG CANCER
    Kathiravelu, Loganathan
    Musto, Grace
    Harding, Gary
    Qing, Gefei
    Badiani, Ketan
    Lother, Sylvain
    Murphy, Leigh C.
    Navaratnam, Sri
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S307 - S307